Yong Yu - Sep 11, 2023 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Sep 11, 2023
Transactions value $
$0
Form type
4
Date filed
9/12/2023, 05:24 PM
Previous filing
Aug 30, 2023
Next filing
Sep 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GNLX Stock Option (right to buy) Award $0 +65K $0.00 65K Sep 11, 2023 Common Stock 65K $22.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.